BioNTech SE’s Strategic Growth in Oncology and mRNA
BioNTech SE (BNTX) has released an update. BioNTech SE is entering a new phase of growth, focusing on expanding its oncology portfolio and advancing mRNA cancer vaccines, as highlighted in their Innovation Series 2024.
Strategic Acquisition and Oncology Focus Justify BioNTech’s Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases. With the acquisition,
BioNTech to Acquire Biotheus for $800 Million to Expand Oncology Portfolio
BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million, securing full global rights to BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
BioNTech Acquires Biotheus to Enhance Cancer Therapies
BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its
BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Biotheus ("Biotheus") today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a programmed death-ligand 1 and vascular endothelial growth factor A-targeting bispecific antibody.
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two companies were already co-developing an experimental antibody that targets two proteins found on cancer cells.
BioNTech to Acquire Biotheus in $950 Million Deal
The tie-up will also expand BioNTech's footprint in China, giving it a local research and development hub for clinical trials, as well as a new biologics manufacturing facility and more than 300 Biotheus employees,
Zacks.com on MSN22h
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
Analysts Are Bullish on Top Healthcare Stocks: Voyager Therapeutics (VYGR), BioNTech SE (BNTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...
Seeking Alpha on MSN1d
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will ...
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...
The Pharma Letter2d
BioNTech to boost oncology offering with buy of Biotheus
Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire ...
What Analysts Are Saying About BioNTech Stock
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
FiercePharma2h
Fierce Pharma Asia—Merck and BioNTech's I-O bispecific buys; AZ CEO's China defense
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...